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Abstract
Rationale Abnormal oscillatory activity associated with N-
methyl-D-aspartate (NMDA) receptor hypofunction is widely
considered to contribute to the symptoms of schizophrenia.
Objective This study aims to characterise the changes pro-
duced by NMDA receptor antagonists and antipsychotics on
accumbal high-frequency oscillations (HFO; 130–180 Hz) in
mice.
Methods Local field potentials were recorded from the nucle-
us accumbens of freely moving mice.
Results Systemic injection of ketamine and MK801 both
dose-dependently increased the power of HFO and produced
small increases in HFO frequency. The atypical antipsychotic
drug, clozapine, produced a robust dose-dependent reduction
in the frequency of MK801-enhanced HFO, whilst haloperi-
dol, a typical antipsychotic drug, had little effect. Stimulation
of NMDA receptors (directly or through the glycine site) as
well as activation of 5-HT1A receptors, reduced the frequency
of MK801-enhanced HFO, but other receptors known to be
targets for clozapine, namely 5-HT2A, 5-HT7 and histamine
H3 receptors had no effect.
Conclusions NMDA receptor antagonists and antipsychotics
produce broadly similar fundamental effects on HFO, as
reported previously for rats, but we did observe several nota-
ble differences. In mice, HFO at baseline were weak or not
detectable unlike rats. Post-injection of NMDA receptor an-
tagonists HFO was also weaker but significantly faster.
Additionally, we found that atypical antipsychotic drugs may
reduce the frequency of HFO by interacting with NMDA and/
or 5-HT1A receptors.
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Introduction
N-methyl-D-aspartate (NMDA) receptor hypofunction has
been proposed to contribute to the symptoms of schizophre-
nia. Acute administration of NMDA receptor antagonists pro-
duces transient psychosis-like activity in healthy humans and
exacerbates the pre-existing symptoms in stabilised schizo-
phrenic individuals (Krystal et al. 1994; Lahti et al. 1995).
This suggests that NMDA receptor antagonists can interact
with neuronal networks that mediate psychosis.
Oscillations recorded in local field potentials (LFP) or elec-
troencephalograms (EEG) are generated by synchronous
changes in the membrane potentials of a population of neu-
rons which can be a few hundred thousand for LFP and sev-
eral million for EEG recordings. Abnormal oscillatory activity
recorded in EEG has been associated with schizophrenia
(Uhlhaas and Singer 2010; Spencer 2011). An increasing
number of studies have used these techniques in attempts to
understand how NMDA receptor hypofunction influences re-
gional brain activity. In experimental rodents, acute applica-
tion of NMDA receptor antagonists is known to influence
oscillations recorded in LFP (Ma and Leung 2000;
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Middleton et al. 2008; Roopun et al. 2008; Kocsis 2012) and
electrocorticograms (Pinault 2008; Phillips et al. 2012).
The nucleus accumbens (NAc) is a brain region that has
been implicated widely in the pathophysiology of schizophre-
nia (Grace 2000). Previously, we identified a high-frequency
oscillation (HFO; 130–180 Hz) recorded in the rat NAc that is
enhanced substantially following systemic or local adminis-
tration of NMDA receptor antagonists (Hunt et al. 2006). In
the NAc, increases in the power of HFO produced by NMDA
receptor antagonists predominate well above changes found in
other frequency bands (Hunt et al. 2010). In recent years, a
number of studies have demonstrated that a HFO band can be
recorded in a variety of neuroanatomical and functionally dis-
tinct regions following injection of NMDA receptor antago-
nist (Hunt et al. 2011; Nicolas et al. 2011; Kulikova et al.
2012; Phillips et al. 2012; Ji et al. 2013; Hiyoshi et al.
2014). Tetrodotoxin infusion to the NAc produces profound
reductions in HFO power which correlate with changes re-
corded in distant cortical sites, indicating the NAc may be
an important generator of HFO (Olszewski et al. 2013a). In
rats, atypical antipsychotic drugs (i.e. clozapine) reduce the
frequency of accumbal HFO to a greater extent than typical
drugs (i.e. haloperidol) (Olszewski et al. 2013b). Whilst both
drug types bind to dopamine D2 receptors, atypical drugs
differ from typical drugs in their mechanism of action.
The improved efficacy of atypical antipsychotic com-
pounds has been attributed to their additional powerful
action at serotonergic receptors, perhaps most notably 5-
HT2A, but also 5-HT1A and 5-HT7 receptors (Meltzer
1999). Compounds that bind to serotonergic receptor
subtypes can block NMDA receptor antagonist-induced
hyperlocomotion (Gleason and Shannon 1997) and attentional
impairments (Higgins et al. 2003; Mirjana et al. 2004) and may
reverse dysfunctional glutamatergic transmission produced by
NMDA receptor antagonists (Ceglia et al. 2004; McOmish
et al. 2012). Amongst the array of actions at other receptor
systems, atypical antipsychotics are known to antagonise hista-
mine H3 receptors (Rodrigues et al. 1995) and potentiate
NMDA receptor currents (Wittmann et al. 2005). These actions
may also contribute to the clinical profile of drugs such as clo-
zapine. Experimental compounds that interact at these sites have
been proposed as novel antipsychotics or adjunctive therapy in
the treatment of schizophrenia (Wittmann et al. 2005; Ito 2009).
To date, the majority of animal model studies have focused
on rats, mainly due to the convenience of the implantation in
this species and for comparison with earlier studies. Effects of
NMDA receptor antagonists on LFP oscillations recorded in
mice, which are also a widely used experimental animal, are
less well investigated. In freely moving mice, ketamine has
been shown to decrease the power of basal hippocampal theta
(3–12 Hz) and increase gamma (30–80 Hz) power
(Lazarewicz et al. 2010); however, effects on HFO remain
largely unknown. A recent study demonstrated that
administration of ketamine generated significantly higher cor-
tical power in the HFO band in Sp4 hypomorphic mice (de-
creased expression of NR1 protein) compared with wild-type
siblings (Ji et al. 2013). However, in this study, a negligible
increase in HFO power was observed in wild-type mice de-
spite the relatively high dose of ketamine used (50 mg/kg).
This may suggest a difference in the generation of HFO be-
tween species. Since, in rats, the NAc appears to be a locus for
generation of HFO, this prompted us to investigate whether
the same holds true for mice. This issue gains importance
considering the increasing number of genetic mouse models
and emergence of optogenetic techniques reliant on modified
genetic background for neuronal specificity. In this study, we
also used a pharmacological strategy to shed light on the




Thirty-four male C57BL/6 and 10 BALB/c mice (20–28 g)
were implanted with a pair of twisted stainless steel electrodes
(125 μm, Science Products, Germany) in the NAc (AP,
1.3 mm; ML, 0.75 mm; DV, 4.2 mm). In all cases, a silver
wire was used as ground/reference electrode connected to a
screw posterior to the bregma. Mice were housed individually
with access to water and food ad libitum. The location of tips
of electrode (electrolytic lesion) was determined on 40-μm
Cresyl violet-stained sections.
Experimental groups
Mice were placed in a recording chamber (35×35×42 cm).
LFP were recorded through a JFET pre-amplifier. The signal
was relayed through a commutator (Plastics One) amplified
×1000, filtered 0.1–1 kHz (A-M Systems, USA) and digitised
4 kHz (Micro1401, CED, Cambridge, UK). Data were stored
on a PC for offline analysis.
Mice were assigned to six experimental groups (see
Supplementary Table 1). Group 1 (n=4) includes
20 min baseline followed by injection of 10, 25 and
50 mg/kg ketamine or vehicle; group 2 (n=5) includes
20 min baseline followed by injection of 0.05, 0.1, 0.25
and 0.5 mg/kg MK801 or vehicle; group 3 (n=6) in-
cludes 20 min baseline followed by injection of
0.25 mg/kg MK801, followed 30 min later by injection
of 1, 5 and 15 mg/kg clozapine or vehicle; group 4 (n=
7) includes 20 min baseline followed by 0.25 mg/kg
MK801, followed 30 min later by 2.0 g/kg glycine,
75 mg/kg NMDA or vehicle; and group 5 (n=6) includes
20 min baseline followed by injection of 0.25 mg/kg
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MK801, followed 30 min later by 1.0 mg/kg 8-OH-
DPAT, 1.0 mg/kg MDL 11, 939 or vehicle. Some mice
(n=10) from groups 4 and 5 also received injection (in-
traperitoneal (i.p.)) of 1.5 mg/kg haloperidol 30 min
post-MK801, and locomotor activity (LMA) was evalu-
ated in four of these mice. Group 6 (n=5) includes
20 min baseline followed by 0.25 mg/kg MK801,
followed 30 min later by injection of a low dose of
haloperidol (0.15 mg/kg) or vehicle and group 7 (n=6)
includes 20 min baseline followed 20 min later by injec-
tion of 0.25 mg/kg MK801, followed 30 min later by
injection of 1.0 mg/kg SB269970, 5.0 mg/kg BF2649
or vehicle. With exception of group 2, locomotor activity
was assessed by beam breaks (Columbus Instruments,
USA). The experiments were performed according to
Latin-square design, whereby each animal with the indi-
vidual groups received all injection(s) assigned in a
pseudorandomised order. All experiments were conduct-
ed in accordance with the European Community guide-
lines on the Care and Use of Laboratory Animals (86/
609/EEC) and approved by a local ethics committee.
Selection of drugs and doses were based on published find-
ings demonstrating reversal of the effects of NMDA receptor
antagonists on motor, cognitive or neurotransmitter effects
(Gleason and Shannon 1997; Ninan and Kulkarni 1998;
Higgins et al. 2003; Mirjana et al. 2004; Ligneau et al. 2007;
Horiguchi et al. 2011; Brabant et al. 2013; Nikiforuk et al.
2013).
Data analysis
LFP signals were inspected for movement artefacts
which when present were removed. These were infre-
quent events which typically corresponded to large am-
plitude deflections of the raw LFP, usually associated
with impact of the headset with the wall of the record-
ing chamber. Mean power spectra of the raw LFP were
carried out on successive 60-s data blocks using a fast
Fourier transform of 4096 points (Spike 2). Total power
(130–180 Hz) and dominant frequency were calculated.
We also analysed 10-min means at the end of the 60-
min time course, unless stated otherwise.
Statistics
Data were analysed using analysis of variance (ANOVA) with
time as the repeated measure followed by the Bonferroni post
hoc test. Means of 10 min with or without drug were com-
pared using one-way ANOVA followed by the Bonferroni
post hoc test or Student’s paired t tests if only two groups were
compared. Differences were considered significant when
p<0.05.
Results
NMDA receptor antagonists dose-dependently increase
the power and frequency of HFO in the mouse nucleus
accumbens
Power spectra analysis of LFP recorded in the mouse NAc
revealed the occurrence of weak spontaneous HFO (130–
180 Hz) in some, but not all mice. When present, spontaneous
HFO were visible, typically as a small bump in the power
spectra around 140 Hz. LFP were recorded before and up to
1 h post-i.p. injection of ketamine (10, 25, 50 mg/kg), MK801
(0.01, 0.1, 0.25, 0.5 mg/kg) or vehicle. Representative time
courses expressed as spectrograms for each drug are shown in
Fig. 1a, d. Repeated-measure ANOVA for HFO power re-
vealed a significant group×time interaction (F(222, 888)=
12.68; p<0.0001). Bonferroni post hoc analysis revealed
HFO power significantly (p<0.001) increased between 1
and 10 min post-injection of 25 mg/kg ketamine. The highest
dose (50 mg/kg) produced a biphasic increase in HFO power,
characterised by an immediate (phase 1) increase occurring in
the first minute (p<0.001), followed by a return to baseline
power and a second increase (phase 2) in power (p<0.01)
occurring 5 to 20min post-injection. There were no significant
differences in power between saline and the 10-mg/kg dose of
ketamine. Consistent with our findings from rats, the power of
HFO positively correlated with beam breaks (Supplementary
Fig. 1). Repeated-measure ANOVA for HFO also revealed a
group×time interaction (F(222, 888)=4.73; p<0.0001), with
Bonferroni post hoc analysis revealing that 25 mg/kg keta-
mine increased HFO between 1 and 10 min (p<0.05), and
50 mg/kg ketamine associated with increases between 1 and
19 min post-injection (p<0.001).
Systemic injection of MK801 also dose-dependently in-
creased the power and frequency of HFO (Fig. 1e, f).
Analyses of the time courses revealed significant group×time
interactions for both HFO power and frequency (F(308,
1540)≤10.59; p<0.001). Increases in HFO power were found
for 0.25 and 0.5 mg/kg MK801, vs. saline, from 19 to 29 min,
respectively. Increases in frequency, with respect to saline,
occurred from 19 min (0.1 mg/kg) to 8 min (0.25 and
0.5 mg/kg).
Clozapine dose-dependently reduces MK801-enhanced
HFO in the mouse nucleus accumbens
We next examined the effect of i.p. injection of the prototyp-
ical atypical antipsychotic compound, clozapine on HFO
30 min post-injection of 0.25 mg/kg MK801. Representative
spectrograms showing the effect of clozapine or vehicle on
HFO from the same mouse are shown in Fig. 2 (A1, A2).
Clozapine dose-dependently reduced motor activation in-
duced by injection of MK801 (one-way ANOVA, F(3, 5)=
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Fig. 1 NMDA receptor antagonists dose-dependently increase the power
and frequency of HFO in the mouse NAc. a Accumbal LFP expressed as
spectrograms showing the effect of intraperitoneal injection of 25 mg/kg
ketamine. b, c Time courses showing the effect of different doses of
ketamine (5, 25, 50 mg/kg, N=4) on the power and frequency of HFO.
d Accumbal LFP expressed as spectrograms showing the effect of intra-
peritoneal injection of 0.25 mg/kgMK801. e, f Time courses showing the
effect of different doses of MK801 (0.01, 0.1, 0.25, 0.5 mg/kg, N=5) on
the power and frequency of HFO. Saline was used as vehicle in both
instances. Arrows indicate time of injection. Values are mean±SEM
Fig. 2 The atypical antipsychotic clozapine dose-dependently decreases
the frequency of HFO in the mouse NAc. A1, A2 Example spectrograms
taken from the samemouse showing the effect of intraperitoneal injection
of clozapine or vehicle on 0.25 mg/kg MK801-enhanced HFO. B Total
number of beam breaks after injection of clozapine. C, D Histograms
showing the effect of different doses of clozapine (0.2, 1, 5 mg/kg, N=
6) or vehicle on the frequency and power of MK801-enhanced HFO.
Values are mean±SEM for a 10-min period (approximately 50-60 min)
post-injection of clozapine and indicated by the shaded area shown on
the time courses in the right-hand figure. **p<0.01; ***p<0.001 com-
pared with vehicle
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64.47; p<0.0001; Fig. 2b). Bonferroni post hoc analysis
showed differences between vehicle and all doses of clozapine
(p<0.01). There were also differences between the lowest
dose of clozapine and the medium and higher doses
(p<0.01) as well as between the medium and higher doses
(p<0.01).
Clozapine (0.2, 1, 5 mg/kg) dose-dependently reduced the
frequency of MK801-enhanced HFO (F(3, 23)=250.6;
p<0.0001, repeated-measure one-way ANOVA; Fig. 2c).
Bonferroni post hoc test revealed significant differences be-
tween vehicle vs. 1 and 5 mg/kg doses of clozapine
(p<0.001). Differences were also found between the lowest
dose at 0.2 mg/kg and higher doses and between the 1- and 5-
mg/kg doses (p<0.001). We did not find a significant effect of
clozapine on MK801-induced HFO power (F(3, 23)=1.6;
p=0.23, repeated-measure one-way ANOVA). Complete
time courses are shown in Fig. 2d. Repeated-measure
ANOVA of the time course revealed a significant group×time
interaction (F(243, 1620)=54.1; p<0.0001). Bonferroni post
hoc revealed the highest dose (5 mg/kg), produced a rapid
effect on HFO with significant differences found from 5 min
(p<0.01) post-injection. The middle dose (1 mg/kg) produced
significant reductions in frequency from 10 min post-injection
(p<0.01) with respect to vehicle. No differences were found
between the lowest dose of clozapine and vehicle.
Haloperidol does not influence the frequency of HFO
in the mouse nucleus accumbens
The effect of i.p. injection of the typical antipsychotic, halo-
peridol, onMK801-enhancedHFO is shown by a spectrogram
in Fig. 3a. Injection of haloperidol (1.5 mg/kg) did not signif-
icantly affect the frequency (group×time, F(83, 1512)=0.69;
p>0.05; Fig. 3b) or power (t=0.172; df=9; p=0.867; Fig. 3c).
To test whether the administered dose had any effect on the
animals, we also measured locomotor activity. Although this
dose of haloperidol did not influence HFO power or frequen-
cy, it did reduce the amount of locomotor activation produced
by MK801 (t=6.56; df=3; p=0.0072; Fig. 3d). We also ex-
amined the effect of a lower dose of haloperidol (0.15 mg/kg)
in a separate group of mice. The time course is shown in
Supplementary Fig. 2. The lower dose did not significantly
influence the frequency (group×time, F(85, 680)=0.65;
p>0.05) or power (group×time, F(85, 680)=0.59; p>0.05)
of MK801-enhanced HFO.
Glycine and NMDA reduce MK801-enhanced HFO
Glycine is a co-agonist of NMDA receptors which at high doses
has been found to have antipsychotic properties in humans (Balu
and Coyle 2015). We examined the effect of glycine at 2 g/kg
approximately 30 min after injection of MK801. Glycine pro-
duced a long-lasting reduction in the frequency of HFO. At 1 h
post-treatment of glycine, the frequency of HFO was 133.3±
7.9 Hz compared with 158.1±1.5 Hz for mice receiving saline
(p=0.028, paired t test; Fig. 4a). Analysis of the time coursewith
repeated-measure ANOVA revealed a group×time interaction
(F(81, 972)=6.99; p<0.0001). Significant reductions in HFO
(p<0.05) occurred from 15 min post-injection of glycine.
Interestingly, the reduction in frequency appeared to occur in
two phases, an initial rapid drop in frequency by approximately
15 Hz, followed by a more gradual reduction in frequency over
Fig. 3 The typical antipsychotic haloperidol does not reduce the
frequency or power of HFO in the mouse NAc. a Example spectrogram
from a representative mouse showing the effect of 1.5 mg/kg i.p.
haloperidol on 0.25 mg/kg MK801-enhanced HFO. b Time courses
showing the frequency of MK801-enhanced HFO before and after injec-
tion of haloperidol or vehicle (N=10). Arrows indicate injection of
MK801and haloperidol, respectively. c Average power of MK801-
enhanced HFO after injection of haloperidol or vehicle. d Total number
of beam breaks after injection of haloperidol was evaluated in four of the
mice. Values are mean±SEM. **p<0.01 compared with vehicle
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the course of the experiment. The power of HFO shows that 1 h
post-glycine was also significantly lower compared with saline
controls (p=0.0125, paired t test; Fig. 4b). A representative
spectrogram showing the effect of glycine on MK801-
enhanced HFO is shown in Fig. 4c. Consistent with the findings
of others (Nilsson et al. 1997), glycine also reduced MK801-
enhanced locomotion with respect to saline (p=0.026, paired t
test; Fig. 4d).
Since glycine is known to potentiate NMDA receptor func-
tion, we next examined the effect of intraperitoneal injection
of 75 mg/kg NMDA on the frequency of MK801-enhanced
HFO. We found that NMDA produced an immediate and
short-lasting reduction in frequency which typically lasted
around 30 min but did not influence the power of HFO.
Mean frequency at 10–20 min post-injection of 75 mg/kg
NMDA was 149±3.2 Hz vs. 167.3±1.4 Hz from saline-
injected mice (p=0.0014, paired t test; Fig. 5a). Analysis of
the time course, using repeated-measure ANOVA, revealed a
group× time interaction (F(81, 972)=9.63; p<0.0001).
Significant reductions in HFO frequency (p<0.01) occurred
between 7 and 22 min post-injection of NMDA. Time courses
are also shown in Fig. 5a, and a representative spectrogram is
shown in Fig. 5b.
Stimulation of 5-HT1A but not blockade of 5-HT2A, 5-HT7
or H3 receptors reduced the frequency
of MK801-enhanced HFO
One-wayANOVA revealed a significant effect on the frequen-
cy of MK801-enhanced HFO (F(4, 29)=14.33; p<0.0001;
Fig. 6a). Bonferroni post hoc test revealed a significant reduc-
tion after injection of 8-OH-DPAT, a potent 5-HT1A agonist,
compared with vehicle and the other drugs tested (p<0.001).
There were no significant changes in HFO frequency after
systemic injection of antagonists at 5-HT2A (1 mg/kg
MDL11939) and 5-HT7 receptors (1 mg/kg SB269970) or
an H3 inverse agonist (5 mg/kg BF2649) with respect to con-
trol. No drug influenced the power of MK801-enhanced HFO
(F(4, 29)=0.74; p=0.75; Fig. 6b). Time course showing the
effect of 8-OH-DPAT on the frequency of MK801-enhanced
HFO is shown in Fig. 6c. Analysis of the time course, using
repeated-measure ANOVA, revealed a group×time interac-
tion (F(85, 850)=10.4; p<0.0001). Significant reductions in
HFO (p<0.01) occurred between 9 and 46 min post-injection
of 8-OH-DPAT.
HFO are smaller amplitude but faster frequency in mice
compared with rats
We carried out a further experiment to compare spontaneous
and enhanced HFO in the BALB/c (n=10) compared with the
C57BL/6 strain. Due to the relatively small power of HFO at
baseline, and the lack of a discernible peak in the spectra, it
was not possible to consistently evaluate its frequency at base-
line. We did, however, evaluate the integrated power for the
HFO band (130–180 Hz) and found no significant difference
for HFO power at baseline (t=1.2; df=35; p=0.23) or post-
injection of 0.25 mg/kg MK801 (t=1.5; df=35; p=0.13).
However, the frequency of MK801-enhanced HFO was sig-
nificantly higher in C57BL/6 compared with BALB/c (t=3.1;
df=35; p=0.0034).
Fig. 4 Glycine reduces the frequency and power of MK801-enhanced
HFO in mice. a, b Histograms showing the effect of 2 g/kg glycine or
saline on the frequency and power of MK801-enhanced HFO. Values are
mean±SEM for a 10-min period (approximately 50–60 min) post-
injection of glycine and indicated by the shaded area shown on the time
courses in the right-hand figure (N=7). c LFP expressed as a spectrogram
from a representative mouse. d Total number of beam breaks post-
injection of glycine or saline. Glycine reduces MK801-induced
hyperlocomotion. *p<0.05; **p<0.01 compared with vehicle
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We conducted further analyses to include data from our
previously published rat studies to compare HFO in C57BL/
6, BALB/c mice and Wistar rats. Analysis of integrated HFO
power at baseline revealed significantly smaller (p<0.01)
power in both strains of mice compared with rats (one-way
ANOVA, F(2, 66)=9.8; p<0.0002). The power between
BALB/c and C57BL/6 was not significantly different.
We also examined the effect of MK801-enhanced HFO
using data from our previously published rat studies at a dose
of 0.15 mg/kg. Although the dose of MK801 was lower in
rats, analysis of the total HFO power 30 min post-injection
revealed that the power of HFO was significantly higher in
rats (p<0.01) compared with both strains of mice, and no
difference between the mouse strains (one-way ANOVA,
F(2, 66)=29.9; p<0.0001). The frequency of MK801-
enhanced HFO was also significantly (p<0.001) higher in
mice (C57BL/6, 170.1±1.2 Hz; BALB/c, 163.2±1.3 Hz)
compared with rats (Wistar, 143.9±1.2 Hz; one-way
ANOVA, F(2, 64)=110.3; p<0.0001). We also found that
the frequency of HFO post-MK801 was significantly higher
in C57BL/6 compared with BALB/c mice (p<0.05).
Clozapine-induced reduction in HFO frequency was more
substantial in C57BL/6 mice compared with Wistar rats
(p<0.001). In mice, clozapine (5 mg/kg) reduced the frequen-
cy by almost 100 Hz, whilst in rats a higher dose of 15 mg/kg
reduced HFO by around 50 Hz. A dose of clozapine at
5 mg/kg in Wistar rats produced small effects on HFO
(Olszewski et al. 2013b).
Discussion
NMDA receptor antagonists produced a sustained increase in
the power and frequency of HFO in the mouse NAc. In the
presence of MK801, the atypical antipsychotic drug, cloza-
pine, dose-dependently reduced the frequency of HFO, whilst
the typical antipsychotic drug, haloperidol, was without effect.
Although we did observe some species differences between
Fig. 5 NMDA reduces the frequency ofMK801-enhanced HFO inmice.
a Histogram showing the effect of 70 mg/kg NMDA or saline on the
frequency of MK801-enhanced HFO (N=7). Values are mean±SEM
for a 10-min period approximately 10–20 min post-injection of NMDA
and indicated by the shaded area shown on the time courses in the right-
hand figure. This experiment was conducted using mice from the glycine
study; therefore, control values shown are those from Fig. 4. b LFP
expressed as a spectrogram from a representative mouse. **p<0.01 com-
pared with vehicle
Fig. 6 Stimulation of 5-HT1A receptors produces a short-lasting reduc-
tion in HFO. a, b Frequency and power of MK801-enhanced HFO (av-
erage 60 min) post-injection of 1.0 mg/kg 8-OH-DPAT (5-HT1A agonist),
1.0 mg/kg MDL 11939 (5-HT2A antagonist), 1.0 mg/kg SB269970 (5-
HT7 antagonist) and 5.0 mg/kg BF2649 (H3 inverse agonist). These com-
pounds mimic some of the different pharmacological activities of
clozapine at specific receptor targets (N=5–6/group). Values are mean±
SEM. c Time course showing the effect of intraperitoneal injection of the
potent 5-HT1A agonist 8-OH-DPAT on the frequency of MK801-
enhanced HFO. First arrow indicates injection of 0.25 mg/kg MK801;
second arrow indicates injection of 8-OH-DPAT or vehicle. ***p<0.001
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mice and rats, the findings reported here are broadly in line
with our previous studies using rats (Hunt et al. 2006;
Olszewski et al. 2013b).
Clozapine and glycine reduce HFO frequency
Clozapine dose-dependently reduced the frequency of HFO in
mice; at the highest dose, an approximate 80Hz reduction was
observed. Effects of clozapine were examined against a back-
ground of MK801-enhanced HFO. The dose of MK801 we
used is similar to earlier studies where behavioural effects of
antipsychotic compounds have been evaluated (Ninan and
Kulkarni 1998; Bradford et al. 2010). As expected, clozapine
dose-dependently reduced MK801-induced locomotor activi-
ty. Haloperidol, at a dose that produced an equivalent reduc-
tion in locomotor activity, did not influence the frequency of
power of HFO, in line with our findings in rats (Olszewski
et al. 2013b). A low dose of haloperidol (0.15 mg/kg), close to
the concentration reported to reverse effect of phencyclidine-
induced increase in cortical pyramidal cell firing (Kargieman
et al. 2007), was also without effect on the increases in HFO
power or frequency produced by MK801. These findings cor-
roborate our earlier study in rats which indicate that reduction
in HFOmay be an electrophysiological signature of ‘atypical-
ity’. Since the baseline power of HFO, in mice, was often
negligible, we could not adequately determine the effect of
clozapine on baseline activity. However, in our previous
study, using rats—which typically display a clear peak in the
HFO range, we observed clozapine, but not haloperidol, re-
duced the frequency of HFO, indicating that atypical drugs
differentially interact with the fundamental mechanisms re-
sponsible for the generation of HFO in the NAc.
Enhancing NMDA receptor neurotransmission at the gly-
cine modulatory site has been proposed as an effective thera-
peutic strategy for the treatment of schizophrenia (Balu and
Coyle 2015). There is good evidence from pre-clinical studies
that demonstrates glycine and compounds which enhance syn-
aptic glycine levels possess antipsychotic efficacy. In animal
models, these compounds reduce psychotomimetic-induced
hyperlocomotion (Boulay et al. 2008), as well as cognitive
deficits induced by NMDA receptor antagonists, including
attentional deficits, novel object recognition and latent inhibi-
tion (Depoortere et al. 2005; Karasawa et al. 2008; Black et al.
2009). Glycine has been shown to reverse deficits in pre-pulse
inhibition in a rat neonatal ventral hippocampal lesion model
(Le Pen et al. 2003). In this study, we found that glycine also
produced a robust reduction in the frequency of HFO. This is
potentially interesting since it corroborates our previous find-
ing that drugs with antipsychotic properties, particularly those
effective in controlling the negative and cognitive symptoms
of schizophrenia, reduce the frequency of HFO in the NAc
(Olszewski et al. 2013b).
Modulation of accumbal HFO by NMDA and 5-HT1A
receptors
Potentiation of NMDA receptor function either directly (injec-
tion of NMDA) or indirectly (glycine) reduced the frequency
of HFO. NMDA receptors play an important role in the activ-
ity of medium spiny neurons, in particular the transition from
hyperpolarised ‘down’ states to ‘up’ ready-to-fire states
(Vergara et al. 2003; Wolf et al. 2005). Both clozapine and
risperidone potentiate NMDA receptor neurotransmission in
cortical neurons (Konradsson et al. 2006). Additionally, using
whole patch cell recordings, it has been shown that bath ap-
plication of clozapine, but not haloperidol or the 5-HT2A an-
tagonist MDL100907, potentiates NMDA receptor currents in
NAc neurons (Wittmann et al. 2005). Notably, sulpiride,
which we showed previously can reduce HFO in rats, also
significantly increased NMDA receptor currents in NAc neu-
rons (Wittmann et al. 2005). These findings point to a pivotal
role played by NMDA receptors in influencing the frequency
of HFO recorded in the NAc. However, other receptor systems
can also influence the frequency of HFO.We found that 8-OH-
DPAT, an agonist at 5-HT1A receptors, reduced the frequency
of NMDA receptor antagonist-enhanced HFO. Clozapine and
several other atypical antipsychotic drugs possess partial ago-
nistic activity at 5-HT1A receptors (for review, see Celada et al.
2013). Compounds which possess combined 5-HT2A/D2 prop-
erties with direct 5-HT1A receptor agonistic properties are ac-
tive in a broad range of models of schizophrenia. These obser-
vations have led to the development of novel antipsychotic
compounds such as aripiprazole and lurasidone (for review,
see Newman-Tancredi and Kleven 2011). The present study
shows that NMDA and 5-HT1A receptors can influence the
frequency of accumbal HFO, whilst it may be inferred we have
not categorically demonstrated that clozapine exerts its effects
on HFO through either of these receptors. Clozapine possesses
antagonist properties at many other receptors, including 5-
HT2A (Canton et al. 1994), 5-HT7 (Roth et al. 1994) and H3
receptors (Rodrigues et al. 1995). Blockade of these receptors
did not influence the frequency of MK801-enhanced HFO,
indicating that clozapine and other antipsychotic compounds
do not exert their effects on HFO through these receptors.
NMDA receptor antagonists appear to preferentially block
NMDA receptors in cortical interneurons (Homayoun and
Moghaddam 2007) and GABAergic neurons of the reticular
nucleus of the thalamus (Troyano-Rodriguez et al. 2014).
Although the major cell type in the NAc is medium spiny
projection neurons, which comprise between 90 and 95 %,
several different classes of interneurons are known to be pres-
ent, including calbindin, parvalbumin, somatostatin and large
cholinergic subtypes (Berke 2011; Russo and Nestler 2013).
Whether NMDA receptor antagonists preferentially target
specific neuronal subtypes warrants investigation, possibly
using optogenetic techniques. As well as local mechanisms,
4532 Psychopharmacology (2015) 232:4525–4535
afferent projections are likely to play a role in the generation of
HFO. Indeed, we have shown previously that local injection
of clozapine to the NAc of rats does not mimic the effects
observed after systemic injection (Olszewski et al. 2013b).
The NAc receives glutamatergic projections from the prefrontal
cortex, amygdala, hippocampus and thalamus (Groenewegen
et al. 1999), and a dense dopaminergic projection from the
ventral tegmental area. Although NMDA receptor antagonists
can increase the firing of prefrontal cortical neurons
(Homayoun and Moghaddam 2007), infusion of TTX to the
prelimbic region of the prefrontal cortex did not disrupt
MK801-enhanced HFO in rats (Olszewski et al. 2013a), sug-
gesting that this region does not drive HFO in the NAc.
Accumbal HFO in mice and rats
In mice, spontaneous HFO were rarely observed, and when
present, they could only be detected as a very small bump in
the averaged power spectra. This is quite different in rats
where spontaneous HFO are clearly visible in the majority
of recordings from the NAc. Given the smaller power at
baseline in mice, it is not surprising that HFO power post-
NMDA receptor antagonist injection was also smaller.
However, the fundamental effects produced by NMDA recep-
tor antagonists on mechanisms generating HFO appear to be
similar in mice and rats. For example, the temporal changes
seen in HFO power generated after NMDA receptor antago-
nists closely follow those previously reported in rats (Hunt
et al. 2006; Nicolas et al. 2011). In both mice and rats, keta-
mine produced a rapid short-lasting increase in power, whilst
MK801 generated HFO which persisted throughout the
course of the experiments. Changes in locomotion and HFO
power positively correlated a finding consistent with our pre-
vious study (Hunt et al. 2006).
With respect to HFO, the frequency of post-injection of
MK801 was 170.1±1.2 Hz compared with 146.3±1.2 Hz in
rats. Mice strains vary substantially in their behavioural re-
sponse to NMDA receptor antagonists and antipsychotic
drugs. Therefore, we also examined HFO in the behaviourally
distinct BALB/c strain of mice (Holmes et al. 2002; Sik et al.
2003; Bothe et al. 2005). Like C57BL/6 mice, HFO in the
BALB/c strain was lower in power but higher in frequency
compared with Wistar rats. Although HFO power was not
different between the two mice strains, we found that the fre-
quency of HFO was slightly lower in BALB/c mice.
When we examined the effects produced by clozapine,
there were certain notable differences between our mice and
previously published rat study. Firstly, the dose of clozapine
efficacious at reducing HFO was lower in mice than rats; a
dose of 5 mg/kg robustly reduced the frequency, by around
80 Hz, in mice, whilst in rats, the same dose produced only
weak 10–20 Hz reductions. Additionally, at this dose in mice
after a subtle increase in power, we observed a dramatic
reduction in power which typically occurred when HFO
reached approximately 100 Hz. In rats, clozapine potentiated
the power of HFO whilst simultaneously reducing HFO. One
possible explanation for this difference is methodology. In our
previous rat study, the dose of MK801 used was submaximal
(Olszewski et al. 2013b). In the current study, using mice, we
used a dose of MK801 that produced close to maximal in-
creases in HFO power; therefore, further potentiation of
HFO power may not be physiologically possible.
Notwithstanding, although there are certain characteristic dif-
ferences between the species, the fundamental effects pro-
duced by NMDA receptor antagonists and antipsychotics on
HFO appear broadly similar in mice and rats.
Conclusions
These findings show that although HFO power and frequency
are different in rats and mice, the effects produced by psy-
chotomimetic and antipsychotic compounds are broadly sim-
ilar in both species. These data also suggest that atypical an-
tipsychotic drugs may reduce the frequency of HFO by
interacting with NMDA and/or 5-HT1A receptors.
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